Clinical impact of the Predict Prostate risk communication tool in men newly diagnosed with non-metastatic prostate cancer: a multi-centre randomised controlled trial.

  title={Clinical impact of the Predict Prostate risk communication tool in men newly diagnosed with non-metastatic prostate cancer: a multi-centre randomised controlled trial.},
  author={David R Thurtle and Valerie Jenkins and Alexandra Lee Jessica Freeman and Matthew Pearson and Gabriel Recchia and Priya Tamer and Kelly Leonard and Paul D. P. Pharoah and Jonathan J Aning and Sanjeev Madaan and Charles Xian-Yang Goh and Serena Hilman and S. Mccracken and Cristian Petre Ilie and Henry Lazarowicz and Vincent J. Gnanapragasam},
  journal={European urology},
Introduction Predict Prostate is a freely-available online personalised risk communication tool for men newly diagnosed with non-metastatic prostate cancer. Its accuracy has been assessed in multiple validation studies but the clinical impact of the tool on patient decision-making had not previously been evaluated. Methods A multi-centre randomised controlled trial was performed across 8 UK centres, wherein newly diagnosed men considering either active surveillance or radical treatment, were… 
2 Citations



Comparative performance and external validation of the multivariable PREDICT Prostate tool for non-metastatic prostate cancer: a study in 69,206 men from Prostate Cancer data Base Sweden (PCBaSe)

The discrimination of PREDICT Prostate significantly outperformed the EAU, NCCN and CAPRA scores for both PCSM and ACM within this cohort overall and demonstrates that PREDCT Prostate is a robust and generalisable model to aid clinical decision-making.

Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model

Clinician estimates of survival were compared against model predictions and reported treatment recommendations with and without seeing PREDICT estimates were compared, suggesting clinicians overestimate cancer-related mortality and radical treatment benefit.

Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.

  • R. HoffmanMary Lo A. Hamilton
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2017
The results suggest that better informing men about treatment options, in particular, conservative treatment, might help mitigate long-term regret, and are timely for men with low-risk cancers who are being encouraged to consider active surveillance.

Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation

Background The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low,

Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model

An individualised prognostic model that contextualises PCa-specific mortality (PCSM) against other cause mortality, and estimates the impact of treatment on survival, and is the first to the authors' knowledge that models potential treatment benefits on overall survival.

Critical review of prostate cancer predictive tools.

Prostate cancer is a very complex disease, and the decision-making process requires the clinician to balance clinical benefits, life expectancy, comorbidities and potential treatment-related side

Decision aids for localized prostate cancer treatment choice: Systematic review and meta‐analysis

Because current decision aids provide information but do not directly facilitate shared decision making, subsequent efforts would benefit from user‐centered design of decision aids that promote shared decisionMaking.

Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29‐Year Follow‐up

Men with clinically detected, localized prostate cancer and a long life expectancy benefited from radical prostatectomy, with a mean of 2.9 years of life gained.